LINC00265 promotes the metastasis and progression of hepatocellular carcinoma by interacting with E2F1 at the promoter of CDK2

Document Type : Original Article


Guangxi Zhuang Autonomous Region Brain Hospital


Objective: This study is aimed to explore the biological function of long intergenic non-protein coding RNA 265 (LINC00265) in hepatocellular carcinoma (HCC) cells, and evaluate its potential as a biomarker.
Materials and Methods: GEPIA database and Kaplan-Meier Plotter database were employed to analyze LINC00265 expression in HCC tissue samples and its predicting value for prognosis. LINC00265 expression in HCC tissues and cells was detected by quantitative real-time polymerase chain reaction (qRT-PCR). After LINC00265 was overexpressed and knocked down in HCC cells, cell counting kit-8 (CCK-8) and 5-Ethynyl-2'-deoxyuridine (EdU) assays were adopted to detect the proliferation of HCC cells. Transwell assay was used to detect the migration and invasion of HCC cells. The interaction between LINC00265 and E2F transcription factor 1 (E2F1) was verified by the catRAPID online analysis tool, RNA pull-down experiment, and RNA binding protein immunoprecipitation (RIP) assay. The binding of E2F1 to the promoter region of cyclin-dependent kinases 2 (CDK2) was detected by dual-luciferase reporter assay and chromatin immunoprecipitation. The regulatory effects of LINC00265 and E2F1 on CDK2 expression were probed by Western blot.
Results: LINC00265 expression was increased in HCC tissues and cells. LINC00265 overexpression promoted the proliferation, migration, and invasion of HCC cells, and knocking down LINC00265 worked oppositely. LINC00265 could bind to E2F1, and LINC00265 could enhance the combination of E2F1 and CDK2 promoter regions, thus promoting CDK2 transcription. LINC00265 overexpression promoted the expression of CDK2 in HCC cells.
Conclusion: Our data suggest that LINC00265 can promote the malignant behaviors of HCC cells by recruiting E2F1 to the promoter region of CDK2.


1. Forner A, Reig M, Bruix J. Hepatocellular carcinoma. Lancet. 2018; 391(10127): 1301-1314.
2. Greten TF, Lai CW, Li G, Staveley-O’Carroll KF. Targeted and immune-based therapies for hepatocellular carcinoma. Gastroenterology. 2019; 156(2): 510-524.
3. Yang JD, Hainaut P, Gores GJ, Amadou A, Plymoth A, Roberts LR. A global view of hepatocellular carcinoma: trends, risk, prevention and management. Nat Rev Gastroenterol Hepatol. 2019; 16(10): 589-604.
4. Dahariya S, Paddibhatla I, Kumar S, Raghuwanshi S, Pallepati A, Gutti RK. Long non-coding RNA: Classification, biogenesis and functions in blood cells. Mol Immunol. 2019; 112: 82-92.
5. Dykes IM, Emanueli C. Transcriptional and post-transcriptional gene regulation by long non-coding RNA. Genomics Proteomics Bioinformatics. 2017; 15(3): 177-186.
6. Sanchez Calle A, Kawamura Y, Yamamoto Y, Takeshita F, Ochiya T. Emerging roles of long non-coding RNA in cancer. Cancer Sci. 2018; 109(7): 2093-2100.
7. Chi Y, Wang D, Wang J, Yu W, Yang J. Long non-coding RNA in the pathogenesis of cancers. Cells. 2019; 8(9): 1015.
8. Chen Z, Zhang Z, Zhao D, Feng W, Meng F, Han S, et al. Long noncoding RNA (lncRNA) FOXD2-AS1 promotes cell proliferation and metastasis in hepatocellular carcinoma by regulating MiR-185/AKT axis. Med Sci Monit. 2019; 25: 9618-9629.
9. Ge H, Yan Y, Yue C, Liang C, Wu J. Long noncoding RNA LINC00265 targets EGFR and promotes deterioration of colorectal cancer: A comprehensive study based on data mining and in vitro Validation. Onco Targets Ther. 2019; 12: 10681-10692.
10. Sun S, Li W, Ma X, Luan H. Long noncoding RNA LINC00265 promotes glycolysis and lactate production of colorectal cancer through regulating of miR-216b-5p/TRIM44 axis. Digestion. 2020; 101(4): 391-400.
11. Gu Y, Wang X, Liu H, Li G, Yu W, Ma Q. SET7/9 promotes hepatocellular carcinoma progression through regulation of E2F1. Oncol Rep. 2018; 40(4): 1863-1874.
12. Tadesse S, Anshabo AT, Portman N, Lim E, Tilley W, Caldon CE, et al. Targeting CDK2 in cancer: challenges and opportunities for therapy. Drug Discov Today. 2020; 25(2): 406-413.
13. Kawakami M, Mustachio LM, Rodriguez-Canales J, Mino B, Roszik J, Tong P, et al. Next-generation CDK2/9 inhibitors and anaphase catastrophe in lung cancer. J Natl Cancer Inst. 2017; 109(6).
14. Patel P, Tsiperson V, Gottesman SRS, Somma J, Blain SW. Dual inhibition of CDK4 and CDK2 via targeting p27 tyrosine phosphorylation induces a potent and durable response in breast cancer cells. Mol Cancer Res. 2018; 16(3): 361-377.
15. Ling L, Lu HT, Wang HF, Shen MJ, Zhang HB. MicroRNA-203 acts as a potent suppressor in septic shock by alleviating lung injury via inhibition of VNN1. Kidney Blood Press Res. 2019; 44(4): 565-582.
16. Jarroux J, Morillon A, Pinskaya M. History, discovery, and classification of lncRNAs. Adv Exp Med Biol. 2017; 1008: 1-46.
17. Mathy NW, Chen XM. Long non-coding RNAs (lncRNAs) and their transcriptional control of inflammatory responses. J Biol Chem. 2017; 292(30): 12375-12382.
18. Grote P, Boon RA. LncRNAs coming of age. Circ Res. 2018; 123(5): 535-537.
19. Wu T, Du Y. LncRNAs: From basic rresearch to Mmedical application. Int J Biol Sci. 2017; 13(3): 295-307.
20. Yang Y, Chen L, Gu J, Zhang H, Yuan J, Lian Q, et al. Recurrently deregulated lncRNAs in hepatocellular carcinoma. Nat Commun. 2017; 8: 14421.
21. Xiao Y, Li C, Wang H, Liu Y. LINC00265 targets miR-382-5p to regulate SAT1, VAV3 and angiogenesis in osteosarcoma. Aging (Albany NY). 2020; 12(20): 20212-20225.
22. Ma L, Kuai WX, Sun XZ, Lu XC, Yuan YF. Long noncoding RNA LINC00265 predicts the prognosis of acute myeloid leukemia patients and functions as a promoter by activating PI3K-AKT pathway. Eur Rev Med Pharmacol Sci. 2018; 22(22): 7867-7876.
23. Zhu Y, Gu L, Lin X, Cui K, Liu C, Lu B, et al. LINC00265 promotes colorectal tumorigenesis via ZMIZ2 and USP7-mediated stabilization of β-catenin. Cell Death Differ. 2020; 27(4): 1316-1327.
24. Yang Z, OuYang X, Zheng L, Dai L, Luo W. Long intergenic noncoding RNA00265 promotes proliferation of gastric cancer via the microRNA-144-3p/Chromobox 4 axis. Bioengineered. 2021; 12(1): 1012-1025.
25. Denechaud PD, Fajas L, Giralt A. E2F1, a novel regulator of ,etabolism. Front Endocrinol (Lausanne). 2017; 8: 311.
26. Sun CC, Zhou Q, Hu W, Li SJ, Zhang F, Chen ZL, et al. Transcriptional E2F1/2/5/8 as potential targets and transcriptional E2F3/6/7 as new biomarkers for the prognosis of human lung carcinoma. Aging (Albany NY). 2018; 10(5): 973-987.
27. Chen H, Chen J, Zhao L, Song W, Xuan Z, Chen J, et al. CDCA5, transcribed by E2F1, promotes oncogenesis by enhancing cell proliferation and inhibiting apoptosis via the AKT pathway in hepatocellular carcinoma. J Cancer. 2019; 10(8): 1846-1854.
28. Chang L, Xi L, Liu Y, Liu R, Wu Z, Jian Z. SIRT5 promotes cell proliferation and invasion in hepatocellular carcinoma by targeting E2F1. Mol Med Rep. 2018; 17(1): 342-349.
29. Yu Y, Zhao D, Li K, Cai Y, Xu P, Li R, et al. E2F1 mediated DDX11 transcriptional activation promotes hepatocellular carcinoma progression through PI3K/AKT/mTOR pathway. Cell Death Dis. 2020; 11(4): 273.
30. Zhao H, Xu Q. Long non-coding RNA DLX6-AS1 mediates proliferation, invasion and apoptosis of endometrial cancer cells by recruiting p300/E2F1 in DLX6 promoter region. J Cell Mol Med. 2020; 24(21): 12572-12584.
31. Liu Q, Gao J, Zhao C, Guo Y, Wang S, Shen F, et al. To control or to be controlled? Dual roles of CDK2 in DNA damage and DNA damage response. DNA Repair (Amst). 2020; 85: 102702.
32. Tadesse S, Caldon EC, Tilley W, Wang S. Cyclin-dependent kinase 2 inhibitors in cancer therapy: an update. J Med Chem. 2019; 62(9): 4233-4251.
33. Abd El-Karim SS, Syam YM, El Kerdawy AM, Abdelghany TM. New thiazol-hydrazono-coumarin hybrids targeting human cervical cancer cells: Synthesis, CDK2 inhibition, QSAR and molecular docking
studies. Bioorg Chem. 2019; 86: 80-96.
34. Tang Z, Li L, Tang Y, Xie D, Wu K, Wei W, et al. CDK2 positively regulates aerobic glycolysis by suppressing SIRT5 in gastric cancer. Cancer Sci. 2018; 109(8): 2590-2598.
35. Li Y, Yang XH, Fang SJ, Qin CF, Sun RL, Liu ZY, et al. HOXA7 stimulates human hepatocellular carcinoma proliferation through cyclin E1/CDK2. Oncol Rep. 2015; 33(2): 990-996.
36. Kim JK, Jung KH, Noh JH, Eun JW, Bae HJ, Xie HJ, et al. Targeted disruption of S100P suppresses tumor cell growth by down-regulation of cyclin D1 and CDK2 in human hepatocellular carcinoma. Int J Oncol. 2009; 35(6): 1257-1264.